Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer

NCT00295893 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00295893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00295893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 27, 2005
Completion date
July 16, 2027
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer